Editor's note

This article was originally published on 22 May 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

The meningococcal franchise opportunity

Sanofi-Pasteur's Menactra (MCV4) had demonstrated by 2008 that the adolescent meningococcal vaccine market could generate substantial revenues in markets with strong national immunisation programme uptake. The US market, where ACIP had recommended MCV4 vaccination for all adolescents aged 11-12 and catch-up vaccination through age 18, was generating annual Menactra revenues of approximately $350m. Novartis Vaccines was positioning Menveo - its own MenACWY conjugate using CRM197 as a carrier - to challenge Menactra on clinical profile and formulation advantages.

The MenB challenge: protein-based vaccines at the frontier

Meningococcal serogroup B (MenB) was the most complex immunological challenge in the meningococcal space: unlike serogroups A, C, W, and Y where capsular polysaccharide conjugation was a well-understood approach, the MenB capsule was immunologically identical to fetal neural tissue and could not be used as an antigen. Novartis's MenB programme - based on reverse vaccinology-derived protein antigens including factor H binding protein (fHbp) - represented the most advanced approach to this historically intractable problem.

MenACWY US Market (2007)
~$350m

Estimated US Menactra revenues in 2007, demonstrating the commercial scale of the adolescent meningococcal market that Novartis was targeting with Menveo

"A company that controls both the MenACWY and MenB spaces will have effectively built an unassailable comprehensive meningococcal franchise - and Novartis is currently the company closest to achieving that position."